Changes to Wörwag Pharma's Advisory Board

Konstantin von Alvensleben and Dr. Dirk Reischig were elected to the Advisory Board of the Wörwag Pharma Group with effect from the beginning of 2023. Dr. Dirk Reischig was also appointed Chairman of the Advisory Board.  

They succeed Prof. Dr. Michael Habs and Ralph Diel, who are stepping down from the Advisory Board. Both have been members of the Advisory Board since 2017. In addition to Prof. Dr. Roderich C. Thümmel, the other Advisory Board members are Dr. Fritz Wörwag, Dr. Marcus Wörwag and Daniela Wörwag, who represent the shareholder family. 

The Advisory Board advises and supports the management and shareholders of Wörwag Pharma on all key issues affecting the company. Gerhard Mayer, Chief Financial Officer of Wörwag Pharma, on the newly composed Advisory Board: "On behalf of the Executive Board, I would like to thank Prof. Dr. Michael Habs and Ralph Diel for their excellent support over the last few years, the constructive discussions and suggestions, and for the trust they have placed in us. At the same time, we would like to extend a warm welcome to Mr. von Alvensleben and Dr. Reischig and look forward to their support!" 

Konstantin von Alvensleben held various management positions in Group companies in the pharmaceutical sector for over 20 years, most recently as CEO of Riemser Pharma GmbH from 2015 until its sale. He has extensive management experience, particularly in key European markets and with regard to company mergers and acquisitions. 

Dr. Dirk Reischig has worked in the pharmaceutical and chemical sector for over 40 years, including positions as Managing Director and CEO. Most recently, as Chairman of the Management Board of the Dr. Willmar Schwabe Group, he significantly expanded its international presence over a period of twelve years. He has been running his consulting firm DR Consulting since 2016 and holds numerous mandates on supervisory and advisory boards.